Continuous ECG monitoring
Confirm whether ECG monitoring is continuous during the period of highest concern, who watches it, and what threshold prompts action. A one-time test is not the same thing as ongoing monitoring.
Rosarito / safety brief
Safety Checklist
For people researching ibogaine treatment in Rosarito: use this as a plainspoken set of questions before considering any facility. It is a safety screen, not a clinical endorsement or a substitute for individualized medical advice.
01 / Starting point
Begin with a reason to pause, not a reason to proceed.
Ibogaine has been associated with serious cardiac risk, including rhythm disturbances. The National Center for Biotechnology Information’s ibogaine overview describes concerns that make screening and supervised risk management central rather than optional.
Before comparing facility claims, place this checklist beside the broader questions in Coyote Measure’s Rosarito safety guidance. A facility’s ability to explain what it will not do is often as important as what it says it can provide.
- 01 Ask for screening criteria in writing. A serious process should identify who may be excluded, delayed, or referred elsewhere before travel or payment commitments are made.
- 02 Ask who reviews the results. Screening has limited value if there is no clear, medically accountable interpretation and decision process.
- 03 Ask how an emergency changes the plan. Obtain a direct explanation of escalation, transfer, resuscitation, and documentation procedures.
02 / Before any treatment
Minimum screening questions
Peer-reviewed safety literature and consensus-oriented risk principles support a careful pre-treatment review. At minimum, ask whether the process includes an ECG with QTc assessment, electrolyte testing, liver and renal panels, and a psychiatric evaluation.
QTc refers to a heart-rhythm measurement derived from an electrocardiogram. Its relevance is tied to the possibility of long QT–related rhythm risk, especially when medication effects, electrolyte abnormalities, or pre-existing cardiac concerns are present.
- ECG and QTc review before treatment, with a clear process for abnormal findings.
- Electrolyte assessment, including prompt attention to clinically significant imbalance.
- Liver and renal panels, because organ function can affect risk review and medication handling.
- Psychiatric evaluation that considers current symptoms, history, medications, and follow-up needs.
03 / On-site readiness
Capabilities to verify directly
Do not infer readiness from wellness language, testimonials, or a general statement that staff are “available.” Ask for specific, documented answers.
Trained medical staff
Ask which trained medical personnel are physically present, their roles during monitoring, and how the facility handles a change in condition outside ordinary hours.
Resuscitation and defibrillation
Verify the presence of emergency resuscitation equipment and defibrillation capability, as well as a documented protocol for its use and for transfer when a higher level of care is needed.
04 / Medication review
Bring the complete picture into the open.
Every prescription, over-the-counter drug, supplement, and recent substance exposure should be disclosed before any decision is made. This includes medications that can affect heart rhythm, medications used for mental health conditions, stimulants, opioids, alcohol, and other psychoactive substances.
The FDA’s warning about drug-associated abnormal heart rhythms illustrates why QT-related risk factors and combinations should not be treated casually. A facility should have a clear medication and substance-interaction review process, including when it requires a pause or outside medical input.
-
List everything, not only what seems relevant.
Bring a current list with names, doses, timing, recent changes, supplements, and non-prescribed substances. Omitting information can undermine any safety review.
-
Do not make abrupt medication changes on a facility’s say-so alone.
Medication changes can carry their own risks. Discuss them with the prescribing clinician or an appropriately qualified independent medical professional who knows your history.
-
Make continuity part of the plan.
Cross-border care can complicate follow-up. Consider how records, aftercare, and urgent needs will be handled once you return; the site’s cross-border considerations are a useful companion to this question.
05 / Stop signs
Red flags that should disqualify treatment
These are reasons to stop and seek independent medical guidance, not problems to negotiate away.
Incomplete or absent screening
Do not proceed if ECG/QTc review, electrolytes, liver and renal panels, or a psychiatric evaluation are missing, rushed, unexplained, or treated as unnecessary. A facility should be able to tell you how results alter its decision-making.
No independent medical oversight
Pause if the person or process responsible for clinical decisions is unclear, unavailable, or not meaningfully independent of marketing and sales pressure. Ask to verify the scope of medical oversight rather than relying on labels alone.
No documented emergency protocol
Do not accept vague assurances. A facility should be able to explain emergency resuscitation and defibrillation readiness, monitoring, escalation, transfer arrangements, and how an emergency is documented.
Pressure to conceal risks or proceed despite concerns
Pressure to minimize cardiac history, psychiatric history, medication use, recent substance exposure, or unanswered questions is a clear stop sign. The independent perspective described on the organization’s approach to safety information is built around keeping uncertainty visible rather than smoothing it over.
Verify, document, and be willing to walk away.
Recommendations here draw on peer-reviewed literature and consensus safety principles. They do not establish efficacy or make any facility safe. Verify independent medical oversight and documented emergency protocols directly with any facility before making decisions.
basic ibogaine treatment context